Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kummar Website

Shivaani Kummar, M.D., F.A.C.P.

Selected Publications

1)  Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S.
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Cancer Chemother. Pharmacol. 71: 981-90, 2013.
2)  Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L.
Cediranib for metastatic alveolar soft part sarcoma.
J. Clin. Oncol. 31: 2296-302, 2013.
3)  Kummar S, Anderson L, Hill K, Majerova E, Allen D, Horneffer Y, Ivy SP, Rubinstein L, Harris P, Doroshow JH, Collins JM.
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2"-deoxyribose in patients with advanced malignancies.
Clin. Cancer Res. 19: 1852-7, 2013.
4)  Kummar S, Doroshow JH.
Molecular targets in cancer therapy.
Expert Rev Anticancer Ther. 13: 267-9, 2013.
5)  Kummar S, Gutierrez ME, Anderson LW, Klecker RW, Chen A, Murgo AJ, Doroshow JH, Collins JM.
Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.
Cancer Chemother. Pharmacol. 2013.
6)  Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Clin. Cancer Res. 19: 3631-9, 2013.
7)  Park SR, Davis M, Doroshow JH, Kummar S.
Safety and feasibility of targeted agent combinations in solid tumours.
Nat Rev Clin Oncol. 10: 154-68, 2013.
8)  Jeong W, Doroshow JH, Kummar S.
United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.
Curr Probl Cancer. 37: 110-44, 2013.
9)  Do K, Doroshow JH, Kummar S.
Wee1 kinase as a target for cancer therapy.
Cell Cycle. 12, 2013.
10)  Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G.
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Clin. Cancer Res. 18: 2344-51, 2012.
11)  Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
Clin. Cancer Res. 18: 1726-34, 2012.
12)  Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH.
Advances in using PARP inhibitors to treat cancer.
BMC Med. 10: 25, 2012.
13)  Do K, Doroshow JH, Kummar S.
Antiangiogenic approaches for the treatment of advanced synovial sarcomas.
Curr Opin Oncol. 24: 425-30, 2012.
14)  Pfister TD, Hollingshead M, Kinders RJ, Zhang Y, Evrard YA, Ji J, Khin SA, Borgel S, Stotler H, Carter J, Divelbiss R, Kummar S, Pommier Y, Parchment RE, Tomaszewski JE, Doroshow JH.
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
PLoS ONE. 7: e50494, 2012.
15)  Kiesel BF, Parise RA, Tjørnelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S, Beumer JH.
LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
J Pharm Biomed Anal. 81-82: 89-98, 2012.
16)  Speranza G, Gutierrez ME, Kummar S, Strong JM, Parker RJ, Collins J, Yu Y, Cao L, Murgo AJ, Doroshow JH, Chen A.
Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors.
Cancer Chemother. Pharmacol. 69: 431-8, 2012.
17)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012.
18)  Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G.
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Clin. Cancer Res. 17: 6831-9, 2011.
19)  Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O'Rourke M, Brenckman W, Tilton R, Liu SH, Jiang Z, Su T, Cheng YC, Chu E.
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Clin Colorectal Cancer. 10: 85-96, 2011.
20)  Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C.
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Clin. Cancer Res. 17: 5755-64, 2011.
21)  Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, Yu Y, Choyke P, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Kummar S, Gutierrez M, Giaccone G.
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Clin. Cancer Res. 17: 1190-9, 2011.
22)  Kummar S.
Foreword. Poly(ADP-ribose) polymerase inhibitors in clinical development.
Curr Probl Cancer. 35: 6, 2011.
23)  Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tomaszewski JE, Doroshow JH.
Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
PLoS ONE. 6: e26152, 2011.
24)  Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G.
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1a in advanced solid tumors.
Clin. Cancer Res. 17: 5123-31, 2011.
25)  Kummar S, Doroshow JH.
Phase 0 trials: expediting the development of chemoprevention agents.
Cancer Prev Res (Phila). 4: 288-92, 2011.
26)  Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH.
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Cancer Res. 71: 5626-34, 2011.
27)  Kummar S, Gutierrez ME, Maurer BJ, Reynolds CP, Kang M, Singh H, Crandon S, Murgo AJ, Doroshow JH.
Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.
Anticancer Res. 31: 961-6, 2011.
28)  Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH.
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Eur. J. Cancer. 47: 997-1005, 2011.
29)  Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, Chen AP, Pommier Y, Doroshow JH, Yang SX.
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Cell Cycle. 10: 4074-82, 2011.
30)  Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD.
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Br J Clin Pharmacol. 72: 294-305, 2011.
31)  Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH.
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Cancer Chemother. Pharmacol. 65: 383-9, 2010.
32)  Speranza G, Doroshow JH, Kummar S.
Adenocarcinoma of the small bowel: changes in the landscape?.
Curr Opin Oncol. 22: 387-93, 2010.
33)  Kummar S.
Evaluation of multiple targeted agents as potential therapies for hepatocellular carcinoma (HCC). Foreword.
Curr Probl Cancer. 34: 130, 2010.
34)  Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
J. Exp. Clin. Cancer Res. 29: 95, 2010.
35)  Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgo AJ, Tomaszewski JE, Doroshow JH, Kinders RJ.
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.
Clin. Cancer Res. 16: 1073-84, 2010.
36)  Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ.
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
J. Clin. Oncol. 28: 4507-12, 2010.
37)  Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ.
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Eur. J. Cancer. 46: 340-7, 2010.
38)  Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, Murgo AJ, Tomaszewski JE, Doroshow JH.
The statistics of phase 0 trials.
Stat Med. 29: 1072-6, 2010.
39)  Kurkjian C, Kummar S, Stewart D, Waxman K, Lam A, Shah S, Paparello J, Katz WA, Barkin RL.
Topics in clinical pharmacology: renal, gastrointestinal, and pain management.
Dis Mon. 56: 187-250, 2010.
40)  Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH.
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements.
Nat Rev Drug Discov. 9: 843-56, 2010.
41)  Kurkjian C, Kummar S.
Advances in the treatment of metastatic colorectal cancer.
Am J Ther. 16: 412-20, 2009.
42)  Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH.
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Cancer Biol. Ther. 8: 2004-9, 2009.
43)  Duffy A, Kummar S.
Metastatic pancreatic adenocarcinoma: current standards, future directions.
Am J Ther. 17: 79-85, 2009.
44)  Kummar S.
Multiple Myeloma. Foreword.
Curr Probl Cancer. 33: 6, 2009.
45)  Gutierrez ME, Kummar S, Giaccone G.
Next generation oncology drug development: opportunities and challenges.
Nat Rev Clin Oncol. 6: 259-65, 2009.
46)  Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
J. Clin. Oncol. 27: 2705-11, 2009.
47)  Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G.
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
Eur. J. Cancer. 45: 741-6, 2009.
48)  Doroshow JH, Kummar S.
Role of Phase 0 trials in drug development.
Future Med Chem. 1: 1375-80, 2009.
49)  Kummar S.
Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Foreword.
Curr Probl Cancer. 33: 72, 2009.
50)  Duffy A, Kummar S.
Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors.
Target Oncol. 4: 267-73, 2009.
51)  Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Designing phase 0 cancer clinical trials.
Clin. Cancer Res. 14: 3675-82, 2008.
52)  Kurkjian C, Kummar S, Murgo AJ.
DNA methylation: its role in cancer development and therapy.
Curr Probl Cancer. 32: 187-235, 2008.
53)  Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB.
Histone deacetylase inhibitors in cancer therapy.
Curr Opin Oncol. 20: 639-49, 2008.
54)  Chen T, Lee MJ, Kim YS, Lee S, Kummar S, Gutierrez M, Hewitt SM, Trepel JB, Levin IW.
Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation.
Anal. Chem. 80: 6390-6, 2008.
55)  Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials: conceptions and misconceptions.
Cancer J. 14: 133-7, 2008.
56)  Donovan EA, Kummar S.
Role of insulin-like growth factor-1R system in colorectal carcinogenesis.
Crit. Rev. Oncol. Hematol. 66: 91-8, 2008.
57)  Kummar S.
The mammalian target of rapamycin (mTOR). Foreword.
Curr Probl Cancer. 32: 160, 2008.
58)  Kurkjian C, Kummar S, Murgo AJ.
The observation that changes in DNA methylation potentially play a role in neoplastic transformation has existed for nearly 30 years. Foreword.
Curr Probl Cancer. 32: 185-6, 2008.
59)  Kurkjian C, Murgo AJ, Kummar S.
Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy.
Clin Colorectal Cancer. 7: 321-4, 2008.
60)  Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Compressing drug development timelines in oncology using phase "0" trials.
Nat. Rev. Cancer. 7: 131-9, 2007.
61)  Chen X, Gardner ER, Gutierrez M, Kummar S, Figg WD.
Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 858: 302-6, 2007.
62)  Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Mol. Interv. 7: 325-34, 2007.
63)  Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ.
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Clin. Cancer Res. 13: 5411-7, 2007.
64)  Hwang K, Scripture CD, Gutierrez M, Kummar S, Figg WD, Sparreboom A.
Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830: 35-40, 2006.
65)  Kummar S, Gutierrez M, Doroshow JH, Murgo AJ.
Drug development in oncology: classical cytotoxics and molecularly targeted agents.
British journal of clinical pharmacology. 62: 15-26, 2006.
66)  Conley BA, Wright JJ, Kummar S.
Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Cancer. 107: 832-40, 2006.
67)  Donovan EA, Kummar S.
Targeting VEGF in cancer therapy.
Current problems in cancer. 30: 7-32, 2006.
68)  Murren J, Modiano M, Kummar S, Clairmont C, Egorin M, Chu E, Sznol M.
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.
Investigational new drugs. 23: 123-35, 2005.
69)  Sportès C, McCarthy NJ, Hakim F, Steinberg SM, Liewehr DJ, Weng D, Kummar S, Gea-Banacloche J, Chow CK, Dean RM, Castro KM, Marchigiani D, Bishop MR, Fowler DH, Gress RE.
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.
Biol. Blood Marrow Transplant. 11: 472-83, 2005.
70)  O'Mahony D, Kummar S, Gutierrez ME.
Non-small-cell lung cancer vaccine therapy: a concise review.
J. Clin. Oncol. 23: 9022-8, 2005.
71)  Noronha V, Shafi NQ, Obando JA, Kummar S.
Primary non-Hodgkin's lymphoma of the liver.
Crit. Rev. Oncol. Hematol. 53: 199-207, 2005.
72)  Kummar S, Shafi NQ.
False elevations in prostate-specific antigen levels affecting patient management.
Clinical advances in hematology & oncology : H&O. 2: 599-601, 2004.
73)  Hobdy EM, Shafi NQ, Kummar S.
Prostate cancer metastasis to supraclavicular lymph node.
Clinical advances in hematology & oncology : H&O. 2: 223-4, 2004.
74)  Kummar S, Shafi NQ.
Metastatic hepatocellular carcinoma.
Clinical oncology (Royal College of Radiologists (Great Britain)). 15: 288-94, 2003.
75)  Farrell MP, Kummar S.
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
Clinical colorectal cancer. 2: 253-6, 2003.
76)  Hobdy EM, Ciesielski TE, Kummar S.
Unusual sites of colorectal cancer metastasis.
Clinical colorectal cancer. 3: 54-7, 2003.
77)  Kummar S, Fogarasi M, Canova A, Mota A, Ciesielski T.
Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma.
Br. J. Cancer. 86: 1884-7, 2002.
78)  Kummar S, Ciesielski TE, Fogarasi MC.
Management of small bowel adenocarcinoma.
Oncology (Williston Park, N.Y.). 16: 1364-9; discussion 1370, 1372-3, 2002.
79)  Kummar S, Ciesielski TE.
Cytokeratin staining for primary and metastatic colorectal cancer.
Clinical colorectal cancer. 1: 187-8, 2001.
80)  Kummar S, Ishii A, Yang HK, Venzon DJ, Kim SJ, Gress RE.
Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-betaI.
Biol. Blood Marrow Transplant. 7: 25-30, 2001.
81)  Fogarasi MC, Zelkowitz RS, Messana SA, Arrighi JA, Seibyl JP, Kummar S.
Positron emission tomography for the evaluation of patients with colorectal cancer.
Clinical colorectal cancer. 1: 117-20, 2001.
82)  Kummar S, Kim SL, Halkar RK, Galt JR.
In-111 labeled octreotide imaging of a primary carcinoid lesion undetected by conventional imaging studies in a patient with.
Clinical nuclear medicine. 21: 634-7, 1996.
Click Here to View Collapsed Bibliography.

This page was last updated on 9/18/2013.